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Background: Endovenous laser ablation is a minimally invasive procedure in the treatment of 
great saphenous vein insufficiency. Procedural criteria (energy delivered according to the selected 
fluence) could affect outcome after treatment, potentially improving the success rate and reduc-
ing complications. However, the optimal values of the required energy per unit volume are not 
known, but on the basis of clinical experience, a range of optimal speed of retraction of the laser 
fiber catheter should exist and strictly depend on the actual vein dimensions.
Methods: The study population included 21 patients. The equipment was a Diomed 30W® laser, 
wavelength 810 nm. Before treatment, three segments of the great saphenous vein were mapped 
and their diameter measured and recorded. The energy delivered to each segment was recorded 
as well as its relationship with vein diameter being evaluated for each vein segment.
Results: A 100% success rate was observed at 12-month follow-up assessment, the discomfort 
complaint 1 week after endovenous laser ablation by 19% of patients was always low (2 or 3 on 
a scale of pain of 10). On the basis of the actual result, which greatly improves our previous 
clinical experience, a range of effective values of speed of retraction of the laser fiber catheter 
(and of the energy per unit volume) is assessed, which strictly depends on the diameter of each 
segment of the vein.
Conclusion: The speed of retraction of the laser fiber catheter should be properly tailored, in 
order to deliver the right energy dose depending on the actual vein diameter. A real-time pro-
cedure can be easily performed using a simple mathematical nomogram.
Keywords: EVLA, great saphenous vein, fluence
Introduction
Chronic venous insufficiency, mainly affecting the great saphenous vein (GSV) and 
varicose veins, are often a source of discomfort, pain, loss of work days, disability, 
and reduced health-related quality of life.1–3 In the adult population, the incidence of 
chronic venous insufficiency is over 20%, and the condition affects women twice as 
often as men.4
Consistent with efforts to reduce post-treatment time and health care spending, 
minimally invasive techniques such as endovenous laser ablation (EVLA) have gained 
wider use. EVLA reportedly compares favorably with conventional surgery, coupled 
with a marked enhancement of quality of life after treatment.5 The success rate of 
EVLA is 88%–100%.6
Such high success rates have derived from a judicious selection of patients according 
to anatomic and clinical criteria. On the procedural side, however, it might be worth 
investigating how energy dosing-related variables (power, type of optic fiber, and fluence) 
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impact on the outcome of laser treatment. Therapeutic effects 
are related to the fact that the laser energy is mainly con-
verted into heat, inducing transmural vein wall destruction 
and irreversible obliteration of the vein. According to the 
recent review of Vuylsteke and Mordon,7 many heat-related 
processes occur and contribute to the result.
Interacting with water, heat induces a fast vaporization 
of the blood in the surrounding vascular region, and steam 
bubbles are created because of the high absorption of laser 
energy in blood.8 Such steam bubbles indicate that blood 
temperature passes the point of boiling at the site of the 
laser tip, thus transferring heat energy homogeneously to 
the inner vessel wall,9 which collapses entrapping the solid 
components of the blood without generating circulating 
thrombi.10 Histologic analysis at biopsy evidenced signs of 
coagulative necrosis in the intimal layer and the tunica media 
of the vein, together with cavities and separations compatible 
with a massive vaporization of their liquid content.10
However, the energy is at least partially absorbed by the 
hemoglobin, leading to clot formation and carbonization 
around the fiber tip and enhancing thermal conduction with 
a mechanisms resembling that of a “heat pipe.”11 Finally, 
direct contact between the fiber tip and the vein wall can 
accidentally provoke perivenous tissue destruction. All of 
them are, however, responsible for vein tissue damage, and 
its consequent fibroblast infiltration is a result of the injury 
response which leads to a replacement of the thrombus with 
collagen deposition. This replacement of the thrombus with 
collagen is necessary for eventual long-term success.12
The first two of the above mechanisms are related to a 
process which develops in the inner volume of the vein, and 
can therefore be thought of as “volume-dependent” effects, 
while direct contact would be a “surface-dependent” effect. 
In other terms, a range of “optimal values” for the energy 
per unit volume (J/v)
opt
 should exist that is able to elicit the 
“right” vascular damage without any unwanted side effect. 
No direct measurements have been performed so far, but 
such a range can be assessed “ex-post,” based on the fact 
that previous treatments have been successful.
The energy J delivered by the laser depends on its power 
P and on the delivering time t. With P being fixed, t is the only 
variable which can be actually controlled through the speed 
of retraction v
r
. Accordingly, it makes sense to define as an 
independent variable the fluence or linear endovenous energy 
density (LEED). For example, the energy delivered for unit 
vessel length L, being:
 LEED = J/L = P t/L = P/v
r
 (1)
As previously stated, the operator can decide the actual 
LEED to be delivered during the procedure by varying the 
speed of retraction v
r
 of the optic fiber catheter by paying 
attention to the position of the catheter and to the acoustic 
signal emitted by the laser equipment (normally one per 
second). Being the effects related to the volume of blood, 
we conclude that more attention should be paid to the 
patient’s vessel dimension, and that a correct and accurate 
procedure should take into account the actual vein diameter 
for dosing the delivered energy. In our previous experience, 
274 patients (41 males, 233 females, mean age 52 years) were 
treated since 2005 with the same protocol described in this 
paper, with LEED values ranging between 70 and 80 J/cm. 
The medium follow-up was 26.6 months, the success rate 
was 95.2%, and failures were mainly detected in the first 
6–12 months. Although non-systematically, we often took a 
single measurement of the vein diameter at the cross-junction 
of the GSV, and found a significant correlation between 
GSV diameter and therapeutic failure (P=0.048; 95% CI 
[confidence interval]).13
To investigate more closely such relationship, we 
designed the present study, where a limited number of 
patients was more accurately monitored through the EVLA 
procedure (diameters were measured at least in three sections, 
but prospectively, the whole vein can be mapped, and the 
LEED values and the corresponding speed of retraction v
r
 of 
the optic fiber were reported), and their clinical procedural 
success were assessed.
Materials and methods
Model study
The therapeutic effects are supposed to be related to the 
ratio between the energy J delivered by the laser equipment 
to a given vascular segment, mainly converted into heat, and 
the blood volume V on which it is delivered. Expressing the 
volume in terms of the vessel diameter D:
 
J
V D
= 4
2π
( )LEED  (2)
Provided a range of optimal values of (J/v)
opt
 is defined, 
which elicits the damaging effects on the vessel walls but 
have no undesired secondary effects for the patient, a range 
of optimal values of LEED, and specifically of retraction 
speed v
opt
, can be assessed depending on the patient’s vein 
diameter:
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According to Equation 3, v
opt
 is expected to be inversely 
proportional to the square of the vessel diameter through a 
“range” of coefficients k, which reflect the range of optimal 
energy delivered for unit volume able to induce the thera-
peutic effect.
clinical study
Patients
The study population was 21 patients treated between January 
2011 and July 2011 for GSV insufficiency. The inclusion 
criteria were vessel diameter ,12 mm (according to Kim 
and Paxton14), incontinence of the saphenofemoral junction, 
distance between the skin surface and the GSV .0.5 cm, no 
vessel tortuosity or endoluminal material, and age .18 years. 
The exclusion criteria were large collaterals of the GSV, 
plexiform or tortuous saphenofemoral junction, lower limb 
vascular disease, inability to walk, pregnancy, breastfeeding, 
hypercoagulability syndromes, deep venous thrombosis, and 
poor general health condition.
In all, 21 EVLA procedures were performed. The case 
series comprised 18 (85.7%) women and three (14.3%) men; 
the mean age was 48 years (range, 42–68). The patients were 
categorized according to the Clinical-Etiology-Anatomy-
Pathophysiology (CEAP) classification for chronic venous 
disease. “C” identifies clinical worsening stages of this 
pathology, from 1 to 6; all of our patients were C2, which is 
evidence of varicose veins.
The most frequent complaint before treatment was pain 
(n=17, 80.95%), followed by heaviness and fatigue (n=14, 
66.6%), warmth (n=11, 52.4%), burning (n=7, 33.3%), 
swelling (n=7, 33.3%), itching (n=3, 14.3%), and tingling 
(n=3, 14.3%).
Preoperative phase
After obtaining informed consent, hemodynamic mapping 
was performed using a Biosound Esaote MyLab 25  ultrasound 
system with a multifrequency probe (5–12 MHz) in B-mode 
and the patient in the orthostatic position. The patient was 
then placed prone in a semilateral decubitus position, and the 
segment of the GSV to be treated was examined.
The geometry of the saphenous vein in our patients showed 
that the vein could be subdivided in three segments having a 
homogeneous diameter value. Consequently, the length of 
the vein was subdivided into three segments of equal length, 
which were then marked on the skin, for a total of 63 segments. 
The proximal segment begins approximately 2–3 cm after 
the saphenous-femoral junction, and ends about the middle 
of the thigh, the intermediate part of the vein anatomically 
includes the section of GSV from the middle to about distal 
third of the thigh, and the distal segment corresponds to the 
distal third of the thigh to about the proximal third of the leg (see 
Figure 1). The diameter of each segment was also measured.
Operative phase
The procedure was performed using local anesthesia (200 mg 
lidocaine in approximately 100 mL of saline) administered 
subcutaneously and inducing tumescence along the segment 
of vein undergoing EVLA. MAC (monitored anesthesia 
care) sedation (midazolam 0.02 mg/kg and remifentanil 
0.025 µg/kg/min) was delivered during the procedure.
Figure 1 Division into segments of great saphenous vein.
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EVLA was performed with percutaneous access to the 
GSV using a diode laser (Diomed 30W®, Food and Drug 
Administration (FDA)-certified; wavelength, 810 nm; power, 
12 W). An FDA-approved endovenous laser kit was employed, 
consisting in a 21 G needle, a 4 Fr sheath, a centimeter-scale 
catheter, and a 45 cm 0.018 steel wire.
The patient was initially positioned in the lateral decubitus 
position (anti-Trendeleburg) to facilitate cannulation of the 
GSV. Subsequently, EVLA was performed on the patient 
lying in the horizontal position without inclination.
During the procedure, using a continuous retraction 
protocol, the energy dose (in Joules) was recorded as the 
probe passed from one segment to the next. As guided by 
the centimeter scale or the acoustic signal, the operator was 
able to accurately adjust the pull-back speed.
Under our protocol, 100 J/cm are delivered empirically to 
the first 3 cm distal to the saphenous-femoral junction (to be 
sure that collapse is locally very effective), thus providing 
300 J in this first segment. In the underlying segments, the 
dose is diminished empirically to 40 J/cm.
Following EVLA, compressive stocking 20–25 mmHg 
was prescribed for 4 weeks and antithrombotic treatment 
(enoxaparin 4,000 IU) for 10 days.
The recommended analgesic therapy was paracetamol 
1 g as needed (up to 3 g per day).
Follow-up assessment
Postoperative clinical and diagnostic assessment was sched-
uled at 1 week, 1 month, 3 months, 6 months, and then yearly 
thereafter. Besides assessing persistent GSV obliteration, clini-
cal examination sought to reveal possible local minor (pain and 
ecchymosis) and major (deep venous thrombosis, phlebitis, skin 
hyperpigmentation, erythema, and infection) complications. 
Pain was evaluated on a 10-point scale, where 10 is the great-
est pain. Ecchymosis was evaluated on a 5-point scale, where 
0 indicates no ecchymosis and 5 denotes extensive ecchymosis 
above and below the treated segment. The outcome was judged 
successful according to the criteria listed in Table 1.
statistical analysis
ANOVA (analysis of variance) was applied to test whether 
there was a statistically significant difference between the 
energy doses per unit length (LEED) delivered to the 63 vein 
segments and between their diameters.
Results
The success rate was 100%, without recanalization. No 
patients were lost to follow-up, whose mean duration 
was 10.3 months. No major complications were noted. 
Four (19%) patients reported experiencing mild pain (2 or 3 
on a scale of 10), and 14 (66.6%) patients presented super-
ficial ecchymosis (1 on a scale of 5) at the 1-week follow-up 
visit and equally affected all the GSV length treated. Pain 
and ecchymosis disappeared at subsequent control (1 month 
after EVLA).
The 21 GSV segments corresponding to the proximal part 
had a mean diameter value of 0.85 cm and a standard deviation 
(SD) of 0.19 cm, and were significantly (P,0.005) different 
from the 21 intermediate segments (mean diameter =0.63 cm, 
SD =0.11 cm) and (P,0.005) from the 21 segments in the 
distal part of the vein (mean diameter =0.69 cm, SD =0.16 
cm). Similarly, also the energy delivered to the 21 proximal 
segments (mean value =678 J, SD =60 J) was significantly 
(P,0.005) larger than that delivered to the 21 intermediate 
segments (mean value =495 J, SD =129 J) and (P,0.005) to 
the distal segments (mean value =422 J, SD =75 J).
According to Equation 3, v
opt
 is expected to be inversely 
proportional to the square of the vessel diameter. We plotted 
v versus D, using as unique data series the proximal, inter-
mediate, and distal segments (see Figure 2).
The dotted and the dashed lines correspond to 
k
min
 =0.08 cm3/s and k
max
 =0.20 cm3/s and reflect the results 
of our clinical experience. The corresponding value for the 
energy per unit volumes are 191 and 76 J/cm3.
Table 1 Procedural success criteria
saphenofemoral 
junction
Vessel patency and absence of thrombotic 
occlusion of the common femoral vein  
Obliteration or patency of the saphenous arch 
without reflux and length ,3 cm  
Patency of the tributaries of the saphenous arch 
without reflux
saphenous trunk Trunk not visible 
Trunk visible but cannot be compressed; no reflux
Deep venous circle no deep venous thrombosis of the treated limb
0
0 0.5 1
D (cm)
1.5
0.1
0.2
0.3
0.4
v 
(c
m
/s
) 0.5
0.6
0.7
Figure 2 Plot of the relationship between retraction velocity (v) and the vessel 
diameter (D).
Notes: Dots = experimental points, lines = plot of equation 3, assuming 
kmin =0.08 cm3/s (dotted) and kmax =0.20 cm3/s (dashed).
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Far from introducing new unnecessary parameters, and 
aiming at simplifying the EVLA procedure, we proposed 
a simple prescription relating the only real “independent” 
parameter controlled by the operator (ie, the retraction speed 
v
opt
 and the patient’s vein diameter). According to Figure 2, 
we estimated the k values corresponding to the lines which 
divided the experimental points into the 25th, 50th, and 75th 
percentiles. Assuming that data below the 25th and above the 
75th percentiles were outliers, those within the range 25–75 
were retained to define a “nomogram” (Table 2), indicating 
the suggested maximal and minimal retraction velocity v 
depending on the actual vein diameter.
Discussion
In our experience, EVLA for great saphenous varicose 
veins is a valid alternative to surgical stripping and com-
pares favorably in long-term outcome. The advantage was 
that clinical success was achieved without the occurrence 
of local short-term complications such as deep venous 
thrombosis, phlebitis, skin hyperpigmentation, paresthesia, 
erythema, or infection. In our previous experience (274 
patients treated with LEED values in the range between 70 
and 80 J/cm unrelated to their GSV diameter), the success 
rate was 95.2%.13
In the present series, where the LEED administered to the 
patients was commensurated to their actual GSV diameter 
(mean LEED value of 60.3 J/cm in the first segment, reduced 
in the other segments to 43.9 and 37.6 J/cm), the clinical 
results were more satisfactory. Such results seem to realize 
a good balance between “underthreshold energy,” with the 
risk of recanalization (many authors have suggested using 
preset linear fluence thresholds to avert early post-procedural 
recanalization15), and “overthreshold energy,” with the risk 
of important side effects (the percentage of local skin and 
nervous complications following low LEED values have been 
reported elsewhere7,16).
A possible weak point is that vein diameters were mea-
sured before anesthesia, disregarding the effect of tumescence 
on the actual vein dimension during the EVLA procedure. 
However we consider such a theoretical effect negligible 
due to the small standardized amount of anesthetics used 
(100 mL) for each patient.
According to our reasoning, to determine the energy 
dose delivered during endovenous ablation, it is neces-
sary to measure the overall delivered energy J, the energy 
per unit length LEED, and the energy per unit volume 
J/V. Both J and LEED are “natural” parameters to be 
controlled, since the energy dose is accurately assess-
able using the pulsed laser, which delivers 12 J per pulse. 
According to LEED=J/L=P/v
r
 the energy dose delivered 
during endovenous ablation could be determined by the 
velocity of the laser retraction. Laser catheter retraction 
devices have been described,16 and currently available 
devices display in real time the energy dose delivered. In 
our experience, under the guidance of a centimeter-scale 
laser and preoperative skin mapping of the GSV, the energy 
being delivered to each segment reliably determined, and 
provided at least eight pulses are delivered to the first 3 
cm of the most proximal segment and then diminished in 
the others, LEED could be easily evaluated. According to 
what was theoretically expected, LEED was found to be 
different for each segment and to be larger in the segments 
with larger diameters.
To evaluate the last parameter (eg, the energy per unit 
volume J/V), which is probably the most significant one to 
understand which physical processes occurred following 
laser energy deposition, no direct measurements were avail-
able, but a simple physical model based on the relationship 
between retraction velocity and vessel diameter afforded 
the indirect estimation. Namely, in all our treatments, the 
delivered energy per unit volume was between 74.1 and 
296.5 J/cm3.
Unfortunately, such values cannot be compared at the 
moment with those eliciting the different physical processes 
(eg, plasma boiling and clot formation) responsible for vas-
cular damage, but they may be useful as reference for further 
in vitro and in vivo investigation.
Moreover, future improvements can be devised. 
 Following preoperative skin mapping of the GSV, sono-
graphic evaluation of the diameters of each vascular seg-
ment, a simple “nomogram” (see Figure 2) or a software 
routine based on Equations 2 and 3 may be developed and 
Table 2 nomogram relating the vessel diameter (cm) and the 
minimal and maximal velocity of retraction (cm/s) estimated as 
25th and 75th percentiles of the experimental data
Vessel  
diameter (cm)
Minimal retraction  
velocity (mm/s)
Maximal retraction 
velocity (mm/s)
0.5 4.1 6.2
0.6 2.9 4.3
0.7 2.1 3.2
0.8 1.6 2.4
0.9 1.3 1.9
1.0 1.0 1.6
1.1 0.9 1.3
1.2 0.7 1.1
1.3 0.6 0.9
1.4 0.6 0.8
1.5 0.5 0.7
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used to pre-assess the optimal retraction velocity of the laser 
tip for each vascular segment to be treated. According to this 
optimal value, the standard intraoperative monitoring of the 
energy dose J and of LEED by means of a centimeter-scale 
catheter and guided by an acoustic signal emitted by the laser 
device, will enable the operator to estimate energy dosing 
to each segment.
Further studies on a larger series of cases, or a comparison 
between patient cohorts treated in the conventional way or 
according to the proposed protocol, are needed to confirm 
our results and to validate our operative proposal.
Conclusion
The novelty of our approach is that of definitely relating the 
energy delivered to the blood vessel to the actual dimension 
of the patient’s vein, defining a stricter range of values for 
the retraction velocity, allowing a kind of “treatment plan” 
for our patients which suits their actual vein dimension along 
the GSV undergoing EVLA.
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